Jak Knowles

CoverCress, Inc. operates as a renewable fuel company. It develops and commercializes field pennycress as an oilseed crop that is used to produces oil for industrial and renewable fuels, and meal for nutritious livestock feed. The company was founded by Vijay Chauhan, Dennis M. Plummer and Mike Roth and is headquartered in St. Louis, MO.

Myotherix, Inc. operates as a biopharmaceutical company focuses on the development of therapies. It focuses on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments. The company was founded by John Kincaid and is headquartered in Emeryville, CA.

Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC.

CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California.

Triumvira Immunologics, Inc. develops and manufactures pharmaceutical products. The company was founded by Jonathan Bramson in 2015 and is headquartered in Hamilton, Canada.

CytoSen Therapeutics, Inc. develops natural killer (NK) cell therapeutics for cancer. It offers nanoparticle processing technology which enables improved ex vivo expansion and activation of NK-cells supporting multiple high dose infusions with anti-cancer cytotoxicity. The company was founded by Stefan O. Ciurea, Dean Lee and Robert Igarashi and is headquartered in Orlando, FL.

Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts.

Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.

RASRx LLC provides research and development laboratories services. The company is headquartered in San Luis Obispo, CA.

Trinds LLC operates as a contract research organization which conducts research in neuromuscular and rare disorders. It offers solutions in clinical operations, data management, patient science liaison services, study measurements, and biostatistics. The company was founded by Avital Cnaan, Heather Gordish-Dressman and Eric Hoffman and is headquartered in Pittsburgh, PA.

Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA.

Affini-T Therapeutics, Inc. is a biotechnology company based in Watertown, MA. Affini-t is focused on developing potentially curative therapies for solid tumor cancers by unlocking the power of T cells and targeting core oncogenic drivers. The company's differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. The company is targeting Kras and other oncogenic and viral driver mutations to open a new and differentiated target space, thereby minimizing the risk of cancer. The company was founded by Jak Knowles and Arjun Goyal, with Jak Knowles serving as the CEO since incorporation.